Status: Not yet recruiting
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).
Participants needed: 98
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Aston Sci. Inc.Updated: Jul 20, 2023Locations: 1
Eligibility criteria
Newly diagnosed stage III (FIGO classification) epithelial ovarian cancer includ... [+5]
Has a history of hypersensitivity or other contraindications to rhuGM-CSF [+5]